Hanmi’s Rosuzet achieves approx. KRW 20 billion sales only in a year
The Hanmi Pharm’s(CEO Kwan-Sun Lee) hyperlipidemia therapy ‘Rosuzet’ achieved approximately KRW 20 billion sales(Jan 2016 to Nov 2016, based on UBIST) in a year after the launch.
For the past 6 months, Rosuzet recorded monthly KRW 2.3 billion prescriptions and 2.2 million tablets, and has been p...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
